Abstract:

Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines, are disclosed herein.
CORRECTED VERSION

INTERNATIONAL SEARCH REPORT

International application No. PCT/US 06/62307

A. CLASSIFICATION OF SUBJECT MATTER
IPCG(S)-A61K31/4965; C07D403/02 (2007.01)
USPC - 514/255.05; 544/405

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
USPC - 514/255.05; 544/405

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
USPTO-WEST (PGPB, USPTO, USOC, JPAB), GOOGLE SCHOLAR/PATENT: substituted pyrazines, intraocular pressure, formulation, pyrazine, inflammatory eye disorders, rho kinase-mediated, glaucoma

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 2005/0153984 A1 (CHEN et al.) 14 July 2005 (14.07.2005); Abstract; para [0032], [0042], [0043], [0045] and [0046]</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1-14</td>
</tr>
<tr>
<td>Y</td>
<td>US 5,219,849 A (LOTTI et al.) 15 June 1993 (15.06.1993); Abstract; col 1, In 44 col 2, In 55; col 4, In 41-56; col 5, In 4-10, 30-65; Claims 1 and 6</td>
<td>1-14</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"V" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"S" member of the same patent family

Date of the actual completion of the international search: 11 July 2007 (11.07.2007)
Date of mailing of the international search report: 02 OCT 2007

Name and mailing address of the ISA/US:
P O Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer: Lee W. Young